Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis
Status:
Unknown status
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of safety of etanercept dose
reduction combined with sulfasalazine in ankylosing spondylitis (AS) patients who have
achieved a significant clinical response.